AHA/ASA guideline recommendations for secondary prevention of stroke: Difference between revisions
< AHA
Aysha Aslam (talk | contribs) |
Aysha Aslam (talk | contribs) |
||
| Line 4: | Line 4: | ||
==2014 AHA/ASA Guidelines for the Secondary Prevention of Stroke== | ==2014 AHA/ASA Guidelines for the Secondary Prevention of Stroke== | ||
===Hypertension=== | ===Hypertension=== | ||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Niacin]] may be considered for patients with low [[HDL cholestero]]l or elevated Lp(a), but its efficacy in pre- venting ischemic stroke in patients with these conditions is not established. Caution should be used with niacin because it increases the risk of [[myopathy]] ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' [[Fibric acid]] derivatives may be considered for patients with [[hypertriglyceridemia]], but their efficacy in pre- venting ischemic stroke is not established''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.''' Treatment with nonstatin lipid-lowering therapies such as fibric acid derivatives, bile acid sequestrants, [[niacin]], and [[ezetimibe]] may be considered in patients who cannot tolerate statins, but their efficacy in preventing stroke is not established ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
==References== | ==References== | ||
Revision as of 23:23, 20 November 2016
|
Ischemic Stroke Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
AHA/ASA guideline recommendations for secondary prevention of stroke On the Web |
|
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for secondary prevention of stroke |
|
FDA on AHA/ASA guideline recommendations for secondary prevention of stroke |
|
CDC on AHA/ASA guideline recommendations for secondary prevention of stroke |
|
AHA/ASA guideline recommendations for secondary prevention of stroke in the news |
|
Blogs on AHA/ASA guideline recommendations for secondary prevention of stroke |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]
2014 AHA/ASA Guidelines for the Secondary Prevention of Stroke
Hypertension
| Class I |
| "1. (Level of Evidence: A)" |
| "2. (Level of Evidence: A)" |
| "3. (Level of Evidence: A)" |
| Class IIb |
| "1. Niacin may be considered for patients with low HDL cholesterol or elevated Lp(a), but its efficacy in pre- venting ischemic stroke in patients with these conditions is not established. Caution should be used with niacin because it increases the risk of myopathy (Level of Evidence: B)" |
| "2. Fibric acid derivatives may be considered for patients with hypertriglyceridemia, but their efficacy in pre- venting ischemic stroke is not established(Level of Evidence: C)" |
| "3. Treatment with nonstatin lipid-lowering therapies such as fibric acid derivatives, bile acid sequestrants, niacin, and ezetimibe may be considered in patients who cannot tolerate statins, but their efficacy in preventing stroke is not established (Level of Evidence: C)" |
| Class IIb |
| "1. (Level of Evidence: B)" |
| "2. (Level of Evidence: C)" |